Lyell Immunopharma, Inc. 8-K

What Happened

• Lyell Immunopharma, Inc. (LYEL) announced its financial results for the quarter ended March 31, 2026 in a press release dated May 6, 2026 and furnished on Form 8-K (Item 2.02). The filing attaches the press release as Exhibit 99.1 and includes the cover page interactive XBRL as Exhibit 104. The Form 8-K was signed by Mark Meltz, General Counsel and Corporate Secretary, on May 6, 2026.

Key Details

• Filing date: May 6, 2026 (Form 8-K).
• Reporting item: Item 2.02 — Results of Operations and Financial Condition (quarter ended March 31, 2026).
• Exhibit 99.1: Press release dated May 6, 2026 announcing the quarter’s financial results.
• Exhibit 104: Cover Page Interactive Data File (Inline XBRL).

Why It Matters

• This 8-K signals that Lyell has released its latest quarterly earnings and financial condition information — important data points (revenue, net income/loss, cash position, and any guidance or operational updates) that investors use to assess company performance. Retail investors should read the attached press release and corresponding SEC filings for the detailed financial metrics and any commentary on business progress or pipeline developments.